Eyevensys SA
Plasmid-based protein therapy for eye diseases
This article was originally published in Start Up
Executive Summary
French start-up Eyevensys SA believes it can improve upon current treatments for AMD, in both ease of administration and frequency of treatment, with a disposable device that injects plasmid-based protein therapies into the ciliary muscle.
You may also be interested in...
Ocular Gene Therapy Sees The Light
Recent scientific advances and some initial biotech successes have spurred investors to look again at gene therapy, a space once given up for dead. Gene therapies seem particularly apt for ocular diseases, but the pathway to approval remains largely uncharted for young companies such as the four we profile in this issue: Avalanche Biotechnologies, Eyevensys, GenSight Biologics, and Hemera Biosciences.
Super-Specialist CROs: Commercializing Pharma R&D Expertise
Outsourcing is not just for mundane pharma services anymore. Increasingly, drugmakers are contracting for specialized R&D assistance they expect to provide strategic as well as tactical advantages.
Spero Therapeutics: Remodeling Antibiotics
Like other companies investigating entirely new ways of treating bacterial infections, biotech start-up Spero is increasingly aware that novel antibiotics may need to travel new clinical and regulatory pathways to market.